Carl read the papersWhat it actually is
Orforglipron is a small-molecule drug, not a peptide. It activates the GLP-1 receptor, the same target as semaglutide and liraglutide, but it is an ordinary chemical rather than a chain of amino acids, so it works as a daily pill taken with or without food.
The FDA approved it as Foundayo on 1 April 2026 for chronic weight management, and the UK's MHRA approved it in August 2026 for weight management and type 2 diabetes. It is a prescription medicine.
How it’s thought to work
- GLP-1 receptor agonism — Activates the GLP-1 receptor. In animal studies it reached the brain regions that control appetite. Less hunger, smaller meals.
- Slowed gastric emptying — Food leaves the stomach more slowly. The label says this is biggest after the first dose and fades over time.
- No food or water rules — Designed to be taken once a day with no food or water restrictions.
- Daily half-life — Roughly 29 to 49 hours, so one tablet a day keeps a steady level.
What the research says
Strong. ATTAIN-1 (phase 3, 3,127 adults without diabetes, 72 weeks) found weight change of -7.5%, -8.4% and -11.2% on the three trial doses, against -2.1% on placebo, counting everyone who started. For context, semaglutide 2.4 mg managed -14.9% in its own 68-week trial (STEP 1); different trials, so not a direct comparison. In type 2 diabetes orforglipron beat oral semaglutide on HbA1c head to head (ACHIEVE-3), with more stomach side effects. ATTAIN-MAINTAIN showed it held most of the weight people had lost on tirzepatide or semaglutide after switching.
- ATTAIN-1 (phase 3, n=3,127, 72 wks): -11.2% on the top dose vs -2.1% placebo; 18.4% lost 20% or more.
- ACHIEVE-3 (type 2 diabetes, 52 wks): beat oral semaglutide on HbA1c at both doses tested.
- More GI events and more stopping for side effects than oral semaglutide (9 to 10% vs 4 to 5%).
- Label: heart rate up 4 to 5 bpm on average; hair loss in 7% of women on it vs 3% of women on placebo.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Label dose | 0.8 mg once daily for at least 30 days, then 2.5 mg, then 5.5 mg; may go to 9, 14.5 or 17.2 mg (maximum), at least 30 days per step. Prescription medicine. |
| Trial vs label numbers | The trials used an investigational formulation at 6, 12 and 36 mg. The label reports the same trial as Foundayo 5.5, 9 and 17.2 mg. The numbers are not interchangeable. |
| Frequency | Once daily, any time, with or without food |
| Route | Oral tablet, swallowed whole |
| Interactions | Maximum 9 mg with strong CYP3A4 inhibitors; pill contraception needs a backup method for 30 days after starting and after each step up |
| Grey-market note | Anything sold as research orforglipron powder or capsules has no reliable link to these doses. The approved tablet is the version with a known dose. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Chronic weight management | the FDA-approved use, alongside diet and activity |
| Type 2 diabetes | approved for this in the UK; beat oral semaglutide on HbA1c |
| Keeping weight off after an injectable | ATTAIN-MAINTAIN switched people from tirzepatide or semaglutide |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
No injection. Foundayo is a tablet taken once a day, at any time, with or without food, swallowed whole (not split, crushed or chewed), and never more than one a day. Each dose step lasts at least 30 days. If you rely on the pill for contraception, the label says to switch or add a barrier method for 30 days after starting and after each increase.
Stacks it appears in
- Not with another GLP-1 — The label says combining it with another GLP-1 receptor agonist is not recommended.
- After an injectable — ATTAIN-MAINTAIN tested switching to it after tirzepatide or semaglutide to hold weight off. That is a switch, not a stack.
Sources
- FOUNDAYO (orforglipron) prescribing information, DailyMed (setid 8ac446c5, v10, effective 29 Jul 2026)
- ATTAIN-1, NEJM 2025 (PMID 40960239)
- ACHIEVE-3 vs oral semaglutide, Lancet 2026 (PMID 41765029)
- ATTAIN-MAINTAIN, Nat Med 2026 (PMID 42120723)
- STEP 1 semaglutide 2.4 mg, NEJM 2021 (PMID 33567185)
- Healio: FDA approves orforglipron (1 Apr 2026)
- GOV.UK/MHRA: UK first in Europe to authorise orforglipron
- SAHPRA, Peptide Products: Public Information (published 26 May 2026)
- WADA 2026 Prohibited List (S0 non-approved substances; S6.B specified stimulants)
